# An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.

> **NCT02316847** · PHASE2 · TERMINATED · sponsor: **Acorda Therapeutics** · enrollment: 126 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** diazepam nasal spray

## Key facts

- **NCT ID:** NCT02316847
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2016-07
- **Final completion:** 2016-09
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2018-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02316847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02316847, "An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02316847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*